1228875-13-5 Usage
Description
(4-fluorotetrahydro-2H-pyran-4-yl)MethanaMine is a chemical compound characterized by the presence of a fluorine-substituted tetrahydro-2H-pyran-4-yl group attached to a methanamine moiety. This unique structure endows the compound with specific properties and functions, making it a versatile building block in the synthesis of pharmaceuticals and organic compounds.
Uses
Used in Pharmaceutical Industry:
(4-fluorotetrahydro-2H-pyran-4-yl)MethanaMine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to confer specific properties and functions to the final products. The presence of the fluorine atom can enhance the bioavailability, metabolic stability, and pharmacological activity of the resulting drugs.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, (4-fluorotetrahydro-2H-pyran-4-yl)MethanaMine serves as a key building block for the creation of a wide range of organic compounds. Its unique structure allows for the development of new molecules with potential applications in various industries, such as materials science, agrochemicals, and specialty chemicals.
Used in Research and Development:
(4-fluorotetrahydro-2H-pyran-4-yl)MethanaMine is utilized in research and development processes to explore its potential in creating new drugs or chemical substances. Its unique structure and properties make it an attractive candidate for the design and synthesis of novel compounds with improved therapeutic effects or innovative applications.
Overall, (4-fluorotetrahydro-2H-pyran-4-yl)MethanaMine is a valuable chemical intermediate with diverse applications across various industries, particularly in the pharmaceutical sector, where its unique structure and properties contribute to the development of innovative and effective products.
Check Digit Verification of cas no
The CAS Registry Mumber 1228875-13-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,8,7 and 5 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1228875-13:
(9*1)+(8*2)+(7*2)+(6*8)+(5*8)+(4*7)+(3*5)+(2*1)+(1*3)=175
175 % 10 = 5
So 1228875-13-5 is a valid CAS Registry Number.
1228875-13-5Relevant articles and documents
CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS
-
Page/Page column 430; 433, (2021/04/10)
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
Solid dispersions containing an apoptosis-inducing agent
-
Page/Page column 102, (2019/03/15)
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
INHIBITORS OF BETA-SECRETASE
-
Paragraph 0227-0229, (2014/03/24)
The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.
